Todd C. Brady - 27 Mar 2026 Form 4 Insider Report for Aldeyra Therapeutics, Inc. (ALDX)

Reporting relationship: President and CEO, Director
Issuer ticker: ALDX
Reported as of: 27 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2026, 16:17:57 UTC
Prior SEC filing: 17 Dec 2025
Next SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd C. Brady

Key filing fact

Todd C. Brady filed Form 4 for Aldeyra Therapeutics, Inc. (ALDX) on 31 Mar 2026.

Key facts

This page summarizes Todd C. Brady's Form 4 filing for Aldeyra Therapeutics, Inc. (ALDX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 31 Mar 2026, 16:17.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001579179 Primary reporting owner

Brady Todd C

Relationship: President and CEO, Director
Address: C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, LEXINGTON
Signature: /s/ Todd C. Brady
Signature date: 31 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALDX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +1,880,510
Change %
Price: $0.000000^*
Shares after: 1,880,510
Date: 27 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,880,510
Exercise price: $1.77
Footnotes: F1

ALDX transaction Derivative

Bonus Units

Award

Transaction value
Shares: +632,318
Change %
Price: $0.000000^*
Shares after: 632,318
Date: 27 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 632,318
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026.

Footnote F2

The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date.